Skip to content

The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.

Elias Dakwar, Frances R. Levin, Richard W Foltin, Edward V. Nunes, Carl L. Hart

Biological Psychiatry September 12, 2013 DOI: 10.1016/j.biopsych.2013.08.009 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized crossover double-blind trial Peer reviewed
Sample size 8
Population Volunteers with active DSM-IV cocaine dependence not seeking treatment or abstinence
Interventions Ketamine Lorazepam
Dose .41 mg/kg or .71 mg/kg ketamine; lorazepam 2 mg
Duration 52-minute intravenous infusions separated by 48 hours; assessments at baseline and 24 hours postinfusion
Measures University of Rhode Island Change Assessment, visual analogue scale craving ratings
Topics Addiction Ketamine Esketamine
Keywords Humans Cocaine-related disorders Lorazepam Hypnotics and sedatives Infusions, intravenous Cross-over studies Double-blind method Behavior, addictive Motivation Cues Dose-response relationship, drug Middle aged Female Young adult Craving Glutamate
Key findings Compared with the active control lorazepam, a single .41 mg/kg ketamine infusion produced a mean 3.9-point gain on the University of Rhode Island Change Assessment (about a 60% increase over preceding values) and a comparable reduction in cue-induced craving; a later .71 mg/kg infusion led to further reductions in cue-induced craving. The authors describe these as promising preliminary effects requiring further research.

Abstract

Background: Cocaine dependence involves problematic neuroadaptations that might be responsive to modulation of glutamatergic circuits. This investigation examined the effects of subanesthetic ketamine infusions on motivation for quitting cocaine and on cue-induced craving in cocaine-dependent participants, 24 hours postinfusion.

Methods: Eight volunteers with active DSM-IV cocaine dependence not seeking treatment or abstinence were entered into this crossover, double-blind trial. Three 52-min intravenous infusions were administered: ketamine (.41 mg/kg or .71 mg/kg) or lorazepam 2 mg, counterbalanced into three orderings in which ketamine .41 mg/kg always preceded the .71 mg/kg dose. Infusions were separated by 48 hours, and assessments occurred at baseline and at 24 hours postinfusion. Outcomes were change between postinfusion and preinfusion values for: 1) motivation to quit cocaine scores with the University of Rhode Island Change Assessment; and 2) sums of visual analogue scale craving ratings administered during cue exposure.

Results: Compared with the active control lorazepam, a single ketamine infusion (.41 mg/kg) led to a mean 3.9-point gain in University of Rhode Island Change Assessment (p = .012), which corresponds to an approximately 60% increase over preceding values. There was a reduction of comparable magnitude in cue-induced craving (p = .012). A subsequent ketamine infusion (.71 mg/kg) led to further reductions in cue-induced craving compared with the control. Infusions were well-tolerated.

Conclusions: Subanesthetic ketamine demonstrated promising effects on motivation to quit cocaine and on cue-induced craving, 24 hours postinfusion. Research is needed to expand on these preliminary results and to evaluate the efficacy of this intervention in clinical settings.

Comparable studies

Other randomized controlled trials on ketamine for addiction, most cited first.

Study Year Design Participants
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Detoxified heroin-addicted patients 2002 Randomized controlled trial n = 70
A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. Adults with alcohol dependence engaged in motivational enhancement therapy 2019 Randomized controlled trial n = 40
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Cocaine-dependent adults 2019 Randomized controlled trial n = 55
Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence Detoxified inpatients with heroin dependence 2007 Randomized controlled trial n = 59
Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder Patients with severe alcohol use disorder 2022 Randomized controlled trial n = 96

Citations in the library

Cited by 81

and 76 more in the library

Cites 11

and 6 more in the library

Explore topics

By condition and practice